Crizotinib-d 5

Overview

Crizotinib-d 5 is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC 50 s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC 50 s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.

Application

Products | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > c-Met/HGFR | Products > Signaling Pathways > ROS Kinase | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-50878S
• CAS No.: 1395950-84-1
• Molecular Formula: C21H17D5Cl2FN5O
• Molecular Weight: 455.37
• Purity: 99.60%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source